DiObex to Present at Canaccord Adams Diabetes and Obesity Conference
Posted on: Wednesday, 4 June 2008, 09:01 CDT
SAN FRANCISCO, June 4 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic disease, announced today that CEO David Cory will deliver a corporate presentation at the upcoming Canaccord Adams Diabetes and Obesity Conference in San Francisco, California. The DiObex presentation will take place on Friday, June 6th at 9 a.m. at the Nikko Hotel, Monterey II Room.
About DiObex
DiObex is a biotechnology company engaged in the development of novel products for metabolic disease. DIO-901 (very low dose glucagon) is in development in two convenient delivery forms for the prevention of nocturnal hypoglycemia induced by insulin intensification. Insulin-induced hypoglycemia, which occurs most frequently at night, is a major limitation in the aggressive management of hyperglycemia in diabetes patients. The DIO-901 disposable device will be applied before bedtime to provide continuous subcutaneous delivery of glucagon during the night. The DIO-901 extended release formulation will be delivered via auto injector before bedtime to slowly release glucagon during the night. DIO-901 has received Fast Track status from the FDA. For more information, visit http://www.diobex.com/.
DiObex, Inc.
CONTACT: Keith Vendola, MD, Corporate Development of DiObex, Inc.,+1-415-551-4115, keith@diobex.com
Web site: http://www.diobex.com/
Source: PRNewswire
Related Articles
- DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
- DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
- Top-Rated TBS Builds on Success With a Development Slate of Primetime Sitcoms and Late-Night Projects
- DiObex, Inc. To Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
- DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
- DiObex Announces Clinical Results of VLD(TM)-Glucagon for Nocturnal Hypoglycemia at the 67th Annual Scientific Sessions of the American Diabetes Association
- Diobex Raises $24 Million Series B Financing Led By Inventages Venture Capital
- Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
- Nuclear Research Project Scrapped
- Crestwood Teachers Walk Today
 |
 |
User Comments (0)
RSS Feeds